Search

Omeros Corp

Закрыт

СекторЗдравоохранение

17.44 -4.23

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

17.41

Макс.

18.23

Ключевые показатели

By Trading Economics

Доход

-38M

13M

Продажи

19M

29M

P/E

Средняя по отрасли

11.485

56.597

Прибыль на акцию

0.02

Рентабельность продаж

46.381

Сотрудники

175

EBITDA

-40M

18M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+89% upside

Дивиденды

By Acuity

Следующий отчет о доходах

12 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

389M

1.4B

Предыдущая цена открытия

21.67

Предыдущая цена закрытия

17.44

Новостные настроения

By Acuity

34%

66%

60 / 339 Рейтинг в Healthcare

Omeros Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 сент. 2026 г., 23:06 UTC

Omeros Corp shares are lower in after-market hours, continuing a trend of declines amid broader market pressure from rising crude oil prices.

10 сент. 2026 г., 20:03 UTC

Omeros Corp shares are lower today, continuing a decline since Wednesday. Trading volume is notably high, reflecting increased investor activity.

3 сент. 2026 г., 19:46 UTC

Omeros Corp shares are higher today, supported by a modest upward trend since Wednesday. Easing Treasury yields may contribute to positive market sentiment.

2 сент. 2026 г., 23:01 UTC

Omeros Corp shares are lower in after-market hours, continuing a downward trend. No specific company news was identified to explain the movement.

1 сент. 2026 г., 19:16 UTC

Omeros Corp shares are lower today, reflecting a decline since Monday's close amid rising global bond yields and inflationary pressures.

31 авг. 2026 г., 23:16 UTC

Omeros Corp shares are higher in after-market trading. No specific news was identified to explain this movement, which appears independent of broader market trends.

28 авг. 2026 г., 20:07 UTC

Omeros Corp shares are lower amid rising U.S. Treasury yields and inflation concerns. The stock peaked early but shifted to a downward trajectory.

27 авг. 2026 г., 22:01 UTC

Omeros Corp shares are lower in after-market trading, reflecting unusual volatility amid broader market concerns over the Federal Reserve's monetary policy and inflation pressures.

26 авг. 2026 г., 23:06 UTC

Omeros Corp shares are higher in after-market hours, with no specific news identified. The stock has gained significantly compared to last month's close.

25 авг. 2026 г., 23:12 UTC

Omeros Corp shares are lower in after-market hours following an unusual trading session, with no specific company news identified to explain the decline.

21 авг. 2026 г., 19:16 UTC

Omeros Corp shares are higher today, trading above their 20-day moving average, despite no specific news to explain the price action.

20 авг. 2026 г., 23:32 UTC

Omeros Corp shares are lower in after-market trading, reversing from a high of 0.70% to a low of -1.99%. No specific news was identified.

19 авг. 2026 г., 22:51 UTC

Omeros Corp shares are trading lower in after-market hours, reaching a session low without any specific news to explain the decline.

18 авг. 2026 г., 23:16 UTC

Omeros Corp. shares are lower in after-market trading, retracing from earlier gains. This decline coincides with mixed performance in Asian markets amid global economic uncertainties.

17 авг. 2026 г., 23:06 UTC

Omeros Corp shares are lower in after-market trading, reaching a low of -1.21% before partially recovering. The stock remains above its 20-day moving average.

15 авг. 2026 г., 00:01 UTC

Omeros Corp shares are higher in after-market trading, reflecting positive momentum as they trade above their 20-day moving average.

14 авг. 2026 г., 23:41 UTC

Omeros Corp shares are lower in after-market trading, reflecting broader market sentiment amid a surprise decline in U.S. retail sales for July.

13 авг. 2026 г., 23:06 UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12 авг. 2026 г., 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11 авг. 2026 г., 23:41 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10 авг. 2026 г., 23:51 UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8 авг. 2026 г., 00:02 UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7 авг. 2026 г., 23:31 UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6 авг. 2026 г., 23:01 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5 авг. 2026 г., 23:51 UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4 авг. 2026 г., 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3 авг. 2026 г., 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1 авг. 2026 г., 00:01 UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31 июл. 2026 г., 23:41 UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30 июл. 2026 г., 16:06 UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

Сравнение c конкурентами

Изменение цены

Omeros Corp Прогноз

Целевая цена

By TipRanks

89% рост

Прогноз на 12 месяцев

Средняя 33 USD  89%

Максимум 33 USD

Минимум 33 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Omeros Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

1

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

60 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat